Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AML19 trial in adults with acute myeloid leukemia or high-risk myelodysplastic syndrome
2014-002195-90Phase 3
- Sponsor
- Cardiff University
- Start
- Jun 2015
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of gemtuzumab ozogamicin, cytarabine and midostaurin in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) (3 arms), sponsored by Cardiff University. Primary endpoint: Overall survival.
02
Drugs
gemtuzumab ozogamicincytarabinemidostaurin
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2014-002195-90.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002195-90.